events/Pharmaceutical Generics and Patent Expirations Steal the Show at CPhI and P-MEC India
A booming generics market and the coming wave of patent expirations for pharmaceuticals has India's pharma companies shrapening their knives – The "pharmerging" markets are also a major topic at this week's CPhI and P-MEC India...
CPhI announces that CPhI and P-MEC India, ran by leading events organiser UBM, is returning to the Bombay Convention and Exhibition Centre, Mumbai (India) from the 3rd to the 5th December 2013. The event will return with an increased scale, continuing its commitment to cater to all sectors of the pharma industry by co-locating with ICSE and BioPh India.
With a view to enhancing the customer experience and ROI value, CPhI India has enhanced the mobile application, now available on all mobile devices with an internet connection, designed to help attendees navigate their way around the event, drive traffic to stands and stay up to date with schedules and speaker events.
More than 1000 Exhibitors
With the addition of hall 7, P-MEC will host even more exhibitors than previous years. Last year, there were 926 exhibitors present and this is expected to rise to 1,000 this year to create the biggest show to date. Free online registration to attend CPhI and P-MEC India is now closed, however registration is still possible in Mumbai, the onsite fee is only INR500.
India has increasingly become a focal point of the pharmaceutical industry and is now the third largest in terms of volume. The country is fast becoming an innovation hub, increasingly matching Western standards, whilst also reducing the costs of manufacturing, showcasing the Indian pharma markets unique position and providing an optimum investment platform for international companies. Outside of the US, India has the highest number of FDA approved facilities (546), and the Indian pharma sector received USFDA approvals for around 40% of all Abbreviated New Drug Approvals (ANDA) during January-July 2013. Further, with R&D investments rapidly advancing, coupled with the rise in generics and supergenerics, India represents a key maturing market, with CPhI and P-MEC India facilitating opportunities to drive and enhance the sector.